Fortis Loses 2nd Bid For $425M Post-Merger Drug Payout
A group of Shire U.S. Holdings merger partner stockholders has lost a second bid for $425 million in post-merger drug development payments after the Delaware Chancery Court found that dismissal of...To view the full article, register now.
Already a subscriber? Click here to view full article